Nuvectis Pharma, Inc.

What they do

Nuvectis is developing precision medicines for oncology and complement-related disorders. Its lead candidate, ciprocopan (NXP100), is an oral, once-daily Factor B inhibitor licensed from Haisco in June 2026 for ex-China rights. The company also holds ex-China rights to NXP200, a brain-penetrant BRAF inhibitor, and owns worldwide rights to NXP900, a SRC/YES1 kinase inhibitor. NXP900 is in Phase 1b trials, including combinations with EGFR and ALK inhibitors in NSCLC.

Revenue drivers

• Ciprocopan (NXP100) — Lead candidate; approved in China for PNH (treatment-naive) in July 2026. No revenue yet; potential royalties/sales in ex-China territories are future drivers.
• NXP200 — BRAF inhibitor licensed from Haisco in June 2026; Phase 1b in China ongoing; potential for solid tumors and primary brain cancer, but no revenue.
• NXP900 — SRC/YES1 inhibitor in Phase 1b; ongoing combos with osimertinib and lorlatinib; no revenue yet.

Recent performance

For the year ended December 31, 2025, net loss was $26.4M, with R&D expenses of $18.2M and G&A of $9.4M. As of June 30, 2026, cash and equivalents were $22.2M, with total assets of $22.4M and shareholder equity of $9.1M. The company had no revenue from inception through June 30, 2026. A follow-on offering in July 2026 raised $115M in gross proceeds, extending cash runway into 1H 2029.

Strategy

Management is prioritizing ciprocopan (NXP100) for a U.S. marketing application, with a pre-IND meeting expected and IND submission in 4Q2026. NXP200 is planned for IND submission in 4Q2026, while NXP900 development is shifting focus to higher-potential combination studies in NSCLC. The company aims to leverage in-licensed late-stage assets to transform into a late-stage clinical organization, with NXP100 and NXP200 providing near-term catalysts and NXP900 for longer-term oncology upside.

Risks

• No revenue and ongoing losses — Since inception, no revenue has been generated, and net losses have continued (e.g., $26.4M in 2025), requiring constant capital raises.
• Clinical and regulatory uncertainties — NXP900 has not completed pivotal trials, and NXP100's U.S. approval is uncertain; failures in ongoing trials could halt development.
• Dependence on third-party partners — NXP100 and NXP200 are licensed from Haisco, and approvals rely on Haisco's data; termination or disputes could jeopardize programs.
• Competition — In complement diseases, iptacopan is an approved twice-daily Factor B inhibitor; NXP100's once-daily advantage may not be enough to win market share.

Outlook

Management expects to complete IND submission for NXP100 in 4Q2026, with a pre-IND meeting with FDA already underway. NXP200's IND submission is also expected in 4Q2026. For NXP900, an update on the osimertinib combination is expected by year-end 2026, and initiation of the lorlatinib combination is expected in 3Q2026. The company projects cash runway into 1H 2029 following the $115M offering.